Barclays PLC Grows Stock Holdings in TScan Therapeutics, Inc. (NASDAQ:TCRX)

Barclays PLC grew its position in shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) by 341.1% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 58,067 shares of the company’s stock after buying an additional 44,903 shares during the quarter. Barclays PLC’s holdings in TScan Therapeutics were worth $289,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. Great Point Partners LLC bought a new position in TScan Therapeutics during the 2nd quarter valued at approximately $5,504,000. Checkpoint Capital L.P. purchased a new position in shares of TScan Therapeutics during the third quarter valued at approximately $4,110,000. State Street Corp increased its stake in shares of TScan Therapeutics by 24.4% during the third quarter. State Street Corp now owns 756,499 shares of the company’s stock valued at $3,767,000 after buying an additional 148,414 shares during the period. Bank of Montreal Can bought a new position in shares of TScan Therapeutics during the second quarter valued at approximately $749,000. Finally, Bank of New York Mellon Corp bought a new stake in TScan Therapeutics in the second quarter valued at $682,000. 82.83% of the stock is currently owned by hedge funds and other institutional investors.

TScan Therapeutics Stock Down 2.4 %

NASDAQ:TCRX opened at $2.40 on Tuesday. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a quick ratio of 9.56. The firm’s 50-day moving average price is $3.56 and its 200-day moving average price is $5.01. The company has a market capitalization of $128.09 million, a PE ratio of -2.26 and a beta of 0.91. TScan Therapeutics, Inc. has a 1-year low of $2.38 and a 1-year high of $9.69.

TScan Therapeutics (NASDAQ:TCRX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.03. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The business had revenue of $1.05 million for the quarter, compared to analyst estimates of $2.86 million. On average, equities analysts predict that TScan Therapeutics, Inc. will post -1.12 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have commented on TCRX shares. Needham & Company LLC restated a “buy” rating and issued a $11.00 price objective on shares of TScan Therapeutics in a report on Wednesday, December 11th. Wedbush restated an “outperform” rating and issued a $7.00 price objective on shares of TScan Therapeutics in a report on Monday, December 23rd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of TScan Therapeutics in a research report on Wednesday, December 11th.

TScan Therapeutics Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.